콘텐츠 본문
논문 해외 국제전문학술지(SCI급) A NOVEL CAFFEIC ACID-L-PIPERONYLPIPERAZINE HYBRIDIZATION COMPOUND HBU-47 INHIBITS LPS-MEDIATED INFLAMMATION IN RAW264.7 MACROPHAGE CELLS
- 학술지 구분 국제전문학술지(SCI급)
- 게재년월 2014-03
- 저자명 박정호
- 학술지명 INTERNATIONAL IMMUNOPHARMACOLOGY
- 발행처명 ELSEVIER SCIENCE BV
- 발행국가 해외
- 논문언어 외국어
- 전체저자수 6
논문 초록 (Abstract)
In the present study, we synthesized a new hybrid compound by coupling caffeic acid and 1-piperonylpiperazine. The synthetic compound, acetyl-caffeic acid-1-piperonylpiperazine (HBU-47), showed pote nt anti-inflammatory effects inhibiting lipopolysaccharide (LPS)-i nduced production of nitric oxide (NO) in RAW264.7 macrophage cells. H BU-47 inhibited LPS-caused induction of inducible NO synthase (iNOS), cyclooxygenase-2, interleukin-6 and interleukin-1 beta in RAW26 4.7 cells in time- and dose-dependent manner. Compared to HBU-47, n either caffeic acid nor 1-piperonylpiperazine displayed significant in hibition of LPS responses. HBU-47 did not affect LPS-caused activation o f mitogen-activated kinases (MAPKs) or I kappa B-alpha. degradati on. Instead, LPS-mediated NF-kappa B activation and DNA bindings of p65, p50 and c-Rel to the NF-kappa B binding site of iNOS promoter w ere inhibited by HBU-47. Overall, our data suggest that the novel c affeic acid hybrid compound downregulates inflammatory responses throu gh inhibition of NF-kappa B and NE-kappa B-dependent gene expressi ons, thus, further suggesting its efficacy as a promising therapeuti c agent. (C) 2014 Elsevier B.V. All rights reserved.
